You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

74 Results
Guidelines and Advice
Updated
Jun 2025
Drug
Other Name(s): Leukeran®
Nov 2024
Drug
Nov 2024
Drug
Other Name(s): Cytosar®
Jul 2025
Drug
Other Name(s): Leustatin®
Nov 2024
Drug
Other Name(s): Jevtana®
Nov 2024
Drug
Other Name(s): Zykadia™
Nov 2024
Drug
Other Name(s): Cotellic™
Nov 2024
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Exceptional Access Program
    lapatinib - Second-Line treatment of HER2 positive metastatic breast cancer in combination with chemotherapy after previous exposure to trastuzumab based treatments, with specific criteria
Exceptional Access Program
    lapatinib - Treatment of HER-2 positive metastatic breast cancer when used in combination with chemotherapy after use of trastuzumab in patients who have an adverse drug reaction or contraindication to trastuzumab therapy
Jul 2025
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
New Drug Funding Program
    Cabazitaxel - Metastatic Castration Resistant Prostate Cancer
ODB - General Benefit
    prednisone
Nov 2024
Regimen
Cancer Type:
Gynecologic, 
Cervix, 
Endometrial, 
Ovary, 
Vulva
Intent: Adjuvant, Palliative
Nov 2024
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Nov 2024

Pages